Drugs for treatment of cancer, ophthalmology and infectious diseases
הזדמנות עסקית זאת היא בת למעלה מחצי שנה
מומלץ לבדוק האם היא עדיין בתוקף
We are a specialty biopharmaceutical company focused on research, development and commercialization of pharmaceutical products based on our proprietary drug delivery technologies for improving the treatment of cancer, ophthalmology and infectious diseases. Our strengths lie in formulatin lipid-based nanoparticles with optimized pharmacokinetics for better efficacy and lower toxicity. We have developed five proprietary technology platforms used in ten products, including three marketed ones and over half of others are in late stage of development. Our company is primarily focused on two arease of business: lifecycle management and New Chemical Entities (NCE) development. Our prprietary drug delivery and furmulation technolgoy enabled the company to transform existing drugs whose patents are about to expire and extend their life cycle by turning them into biobetters. In most cases, these bio-betters are likely to be the first and only in their category with complex technology barrier against nanosimilars development. In the area of NCE development, by using proprietary lipid-based formulation platforms, we are able to effectively find design strategies for compounds with inadequate solubility or toxicity. TLC388 is demonstrative of our company's development capability from compound zero to lead compound and scale up all the way to US IND in just two years. TLC388 has been granted Orphan Drug Designation by both EU EMA and US FDA for the treatment of HCC. CFDA has also accepted TLC388 into the "Green Path" program.